Known and little-known facts about acetylsalicylic acid

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Acetylsalicylic acid (ASA) remains one of the most widely used drugs in cardiology due to its antiplatelet properties. However, long-term use of ASA is associated with the risk of side effects, especially from the gastrointestinal tract. The choice of ASA form plays an important role in minimizing side effects. Enteric-coated forms reduce the risk of gastropathy, but often have low bioavailability and insufficient antiplatelet effect, especially in patients with concomitant obesity and diabetes mellitus. Buffered forms demonstrate better tolerability and maintain high bioavailability, which makes them preferable for long-term therapy. Also, as a preventive measure for gastrointestinal complications, it is recommended to prescribe proton pump inhibitors, especially in patients with a high risk of gastrointestinal bleeding.

全文:

受限制的访问

作者简介

Olga Ostroumova

Russian Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University (Sechenov University)

编辑信件的主要联系方式.
Email: ostroumova.olga@mail.ru
ORCID iD: 0000-0002-0795-8225
SPIN 代码: 3910-6585

Dr. Sci. (Med.), Professor, Head of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi, Professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases

俄罗斯联邦, Moscow; Moscow

Svetlana Litvinova

Russian Medical Academy of Continuous Professional Education

Email: batyukina.svetlana@yandex.ru
ORCID iD: 0000-0003-1316-7654

Cand. Sci. (Med.), Assistant of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi

俄罗斯联邦, Moscow

Natalia Plotnikova

Russian Medical Academy of Continuous Professional Education

Email: na_tasah_90@mail.ru
ORCID iD: 0000-0001-5454-9339

Cand. Sci. (Med.), Associate Professor of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi

俄罗斯联邦, Moscow

Aleksey Kochetkov

Russian Medical Academy of Continuous Professional Education

Email: ak_info@list.ru
ORCID iD: 0000-0001-5801-3742
SPIN 代码: 9212-6010

Cand. Sci. (Med.), Associate Professor of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi

俄罗斯联邦, Moscow

Alexander Arablinsky

Russian Medical Academy of Continuous Professional Education

Email: alexar-card@mail.ru
ORCID iD: 0000-0002-2117-5016

Dr. Sci. (Med.), Associate Professor, Professor of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi

俄罗斯联邦, Moscow

Sofya Eremina

Russian Medical Academy of Continuous Professional Education

Email: sofya.eremina@mail.ru
ORCID iD: 0000-0001-7989-354X

2nd year resident of the Department of Therapy and Polymorbid Pathology named after Academician M.S. Vovsi

俄罗斯联邦, Moscow

参考

  1. Montinari M.R., Minelli S., De Caterina R. The first 3500 years of aspirin history from its roots – A concise summary. Vascul Pharmacol. 2019;113:1–8. doi: 10.1016/j.vph.2018.10.008.
  2. Arabidze G.G., Mamedov M.N., Konstantinov V.O., et al. Management of patients with hypertriglyceridemia. Focus on diabetes mellitus. Int J Heart Vascul Dis. 2024;12(42.1):6–44. doi: 10.24412/2311-1623-2024-42S1-6-44.
  3. WHO newsletter. Cardiovascular diseases. [Date of access 06.03.2025]. URL: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
  4. Patrono C., Garia Rodriguez L.A., Landolfi R., Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–83. doi: 10.1056/NEJMra052717.
  5. Барбараш О.Л., Карпов Ю.А., Панов А.В. и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):6110. [Barbarash O.L., Karpov Yu.A., Panov A.V., et al. Clinical practice guidelines for Stable coronary artery disease. Rus J Cardiol. 2024;29(9):6110. (In Russ.)]. doi: 10.15829/1560-4071-2024-6110.
  6. Клинические рекомендации. Ишемический инсульт и транзиторная ишемическая атака. Год утверждения: 2024. Clinical guidelines. Ischemic stroke and transient ischemic attack. Year of approval: 2024.
  7. Клинические рекомендации. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Год утверждения: 2024. [Clinical guidelines. Acute myocardial infarction with ST-segment elevation of the electrocardiogram. Year of approval: 2024. (In Russ.)].
  8. Клинические рекомендации. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Год утверждения: 2024. [Clinical guidelines. Acute coronary syndrome without ST-segment elevation of the electrocardiogram. Year of approval: 2024. (In Russ.)].
  9. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей, 2019 г. [National guidelines for the diagnosis and treatment of diseases of the arteries of the lower extremities, 2019. (In Russ.)].
  10. Vrints C., Andreotti F., Koskinas K.C., et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415–537. doi: 10.1093/eurheartj/ehae177.
  11. Mazzolai L., Teixido-Tura G., Lanzi S., et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538–700. doi: 10.1093/eurheartj/ehae179.
  12. Byrne R.A., Rossello X., Coughlan J.J., et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826. doi: 10.1093/eurheartj/ehad191.
  13. Visseren F.L.J., Mach F., Smulders Y.M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337. doi: 10.1093/eurheartj/ehab484.
  14. Knuuti J., Wijns W., Saraste A., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77. doi: 10.1093/eurheartj/ehz425.
  15. Орлова А.Я. Некоторые вопросы назначения ацетилсалициловой кислоты в клинической практике. Артериальная гипертензия. 2015;21(5):536–44. [Orlova A.Ya. Some issues of prescribing acetylsalicylic acid in clinical practice. Arter Hypertens. 2015;21(5):536–44. (In Russ.)]. doi: 10.18705/1607-419X-2015-21-5-536-544.
  16. Драпкина О.М., Концевая А.В., Калинина А.М. и др. Профилактика хронических неинфекционных заболеваний в Российской Федерации. Национальное руководство 2022. Кардиоваскулярная терапия и профилактика. 2022;21(4):5–232. [Drapkina O.M., Kontsevaya A.V., Kalinina A.M., et al. Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines 2022. Cardiovasc Ther Prevent. 2022;21(4):5–232. (In Russ.)]. doi: 10.15829/1728-8800-2022-3235.
  17. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. doi: 10.1136/bmj.324.7329.71.
  18. Juul-Möller S., Edvardsson N., Jahnmatz B., et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. 1992;340(8833):1421–5. doi: 10.1016/0140-6736(92)92619-q.
  19. Steg P.G., Huber K., Andreotti F., et al. Bleedingin acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2011;32(15):1854–64. doi: 10.1093/eurheartj/ehr204.
  20. Mayersohn M., Chow M.S., Kostenbauder H.B., Rowland M. Aspirin. J Am Pharm Assoc. 1977;17(2):107–12. doi: 10.1016/s0003-0465(16)34247-1.
  21. Jirmar R., Widimsky P. Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin? Cor et Vasa. 2018;60(2):e165–8. doi: 10.1016/j.crvasa.2017.05.011.
  22. Levy G. Clinical pharmacokinetics of salicylates: a re-assessment. Br J Clin Pharmacol. 1980;10(Suppl. 2): S285–90. doi: 10.1111/j.1365-2125.1980.tb01811.x.
  23. Сидоров А.В. Антитромботический эффект препаратов ацетилсалициловой кислоты в разных лекарственных формах: есть ли разница? Российский кардиологический журнал. 2021;26(10):4734. [Sidorov A.V. Antithrombotic effect of different acetylsalicylic acid drug formulations: is there a difference? Rus J Cardiol. 2021;26(10):4734. (In Russ.)]. doi: 10.15829/1560-4071-2021-4734.
  24. Cox D., Maree A.O., Dooley M., et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37(8):2153–8. doi: 10.1161/01.STR. 0000231683.43347.ec.
  25. Clerici B., Cattaneo M. Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review. J Cardiovasc Dev Dis. 2023;10(4):137. doi: 10.3390/jcdd10040137.
  26. Graham D.Y., Smith J.L. Aspirin and the stomach. Ann Intern Med. 1986;104(3):390–8. doi: 10.7326/0003-4819-104-3-390.
  27. Кобалава Ж.Д., Толкачева В.В., Кафтанов А.Н., Гаврилов Д.В. Эффективность препарата буферной формы ацетилсалициловой кислоты по сравнению с другими препаратами у пациентов с сердечно-сосудистыми заболеваниями в реальной клинической практике: результаты наблюдательного ретроспективного исследования КАРДИНАЛ. Российский кардиологический журнал. 2023;28(12):5709. [Kobalava Zh.D., Tolkacheva V.V., Kaftanov A.N., Gavrilov D.V. Effectiveness of buffered acetylsalicylic acid compared to other drugs in diseases patients in clinical practice: results of the CARDINAL observational retrospective study. Rus J Cardiol. 2023;28(12):5709. (In Russ.)]. doi: 10.15829/1560-4071-2023-5709.
  28. Kedir H.M., Sisay E.A., Abiye A.A. Enteric-Coated Aspirin and the Risk of Gastrointestinal Side Effects: A Systematic Review. Int J Gen Med. 2021;14:4757–63. doi: 10.2147/IJGM.S326929.
  29. Haastrup P.F., Grønlykke T., Jarbøl D.E. Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid. Basic Clin Pharmacol Toxicol. 2015;116(3):212–5. doi: 10.1111/bcpt.12362.
  30. Bhatt D.L., Grosser T., Dong J.F., et al. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017;69(6):603–12. Doi: 10.1016/j. jacc.2016.11.050.
  31. Ломакин Н.В., Русанова А.В., Бурячковская Л.И. и др. Сравнение антиагрегантной эффективности разных форм ацетилсалициловой кислоты. Сердце: журнал для практикующих врачей. 2014;78(4):206–15. [Lomakin N.V., Rusanova A.V., Buryachkovskaya L. I., et al. Comparison of antiplatelet efficacy of different forms of acetylsalicylic acid. Heart: J Pract Physic. 2014;78(4):206–15. (In Russ.)].
  32. Angiolillo D.J., Prats J., Deliargyris E.N., et al. Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation. Clin Pharmacokinet. 2022;61(4):465–79. doi: 10.1007/s40262-021-01090-2.
  33. Sagar K.A., Smyth M.R. A comparative bioavail- ability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal. 1999;21(2):383–92. doi: 10.1016/s0731-7085(99)00177-6.
  34. Rocca B., Fox K.A.A., Ajjan R.A., et al. Antithrombotic therapy and body mass: an expert posi- tion paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672–86. doi: 10.1093/eurheartj/ehy066.
  35. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. клинические рекомендации. Научно-практическая ревматология. 2018;56:1–29. [Karateev A.E., Nasonov E.L., Ivashkin V.T., et al. Rational use of nonsteroidal anti-inflammatory drugs. clinical guidelines. Rheumatol Sci Pract. 2018;56:1–29. (In Russ.)]. doi: 10.14412/1995-4484-2018-1-29.
  36. Huang E.S., Strate L.L., Ho W.W., et al. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med. 201;124(5):426–33. doi: 10.1016/j.amjmed.2010.12.022.
  37. Яковенко Э.П., Краснолобова Л.П., Яковенко А.В. и др. Влияние препаратов ацетилсалициловой кислоты на морфо-функциональное состояние слизистой оболочки желудка у кардиологических пациентов пожилого возраста. Сердце. 2013;12(3):145–50. [Yakovenko E.P., Krasnolobova L.P., Yakovenko A.V., et al. The effect of acetylsalicylic acid preparations on the morphofunctional state of the gastric mucosa in elderly cardiological patients. Serdze. 2013;12(3):145–50. (In Russ.)].
  38. Takada M., Fujimoto M., Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther. 2014;52(3):181–91. doi: 10.5414/CP201997.
  39. Баркаган З.С., Котовщикова Е. Ф. Сравнительный анализ основных и побочных эффектов различных форм ацетилсалициловой кислоты. Клин. фармакология и терапия. 2004;13(3):1–4. [Barkagan Z.S., Kotovshchikova E.F. Comparative analysis of the main and side effects of various forms of acetylsalicylic acid. Clin Pharmacol Ther. 2004;13(3):1–4. (In Russ.)].
  40. Smale S., Tibble J., Sigthorsson G., Bjarnason I. Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine. Best Pract Res Clin Gastroenterol. 200;15(5):723–38. doi: 10.1053/bega.2001.0231.
  41. Schneider A.R., Benz C., Riemann J.F. Adverse effects of nonsteroidal anti-inflammatory drugs on the small and large bowel. Endoscopy. 1999;31(9):761–7. doi: 10.1055/s-1999-1975.
  42. Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике. Российский кардиологический журнал. 2022;27(7):5155. [2021. ESC Guidelines on cardiovascular disease prevention in clinical practice. Rus J Cardiol. 2022;27(7):5155. (In Russ.)]. doi: 10.15829/1560-4071-2022-5155.
  43. Scally B., Emberson J.R., Spata E., et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet. Gastroenterol Hepatol. 2018;3(4):231–41. doi: 10.1016/S2468-1253(18)30037-2.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2025